Prepared by: The Management of Dyslipidemia for Cardiovascular Risk Reduction Work Group With support from: The Office of Quality and Patient Safety, VA, Washington, DC & Office of Evidence Based Practice, U.S. Army Medical Command Based on evidence reviewed through May 16, 2019 Table of Contents II. Dyslipidemia is Defined by Risk for Cardiovascular Disease 5 III. About this Clinical Practice Guideline 6 a. Grading Recommendations 7 b. Reconciling 2014 Clinical Practice Guideline Recommendations 8 c. Peer Review Process 9 B. Summary of Patient Focus Group Methods and Findings 9 C. Conflicts of Interest 10 D. Scope of this Clinical Practice Guideline 10 a. Populations Included in this Guideline 10 b. Populations Excluded from this Guideline 10 E. Patient-centered Care 11 F. Highlighted Features of this Clinical Practice Guideline 11 b. Treatment Intensity Instead of Lipid Targets 11 G. Shared Decision Making 12 IV. Guideline Work Group 13 V. Algorithm 14 Algorithm: Management of Dyslipidemia for Cardiovascular Risk Reduction 15 VI. Recommendations 17 A. Screening and Assessment of Cardiovascular Risk 19 B. Pharmacotherapy, Supplements, and Nutraceuticals 25 a. Primary Prevention 25 b. Secondary Prevention 32 c. Other Medications, Supplements, and Nutraceuticals 39 d. Monitoring and Adherence 47 C. Lifestyle Interventions 52 VII. Knowledge Gaps and Recommended Research 56 A. Comparison of Medical Therapies in Primary and Secondary Prevention 56 a. Primary Prevention 56 b. Secondary Prevention 57 B. Effectiveness of Non-statin Monotherapy for Primary Prevention 57 C. Safety of Newer Therapies 57 D. Stratifying Primary Prevention Benefits by Patient Risk Estimates 57 E. Prospective Studies to Improve Statin Adherence 57 F. Prospective Comparative Study of Risk Prediction Strategies 58 G. Prospective Comparison of Risk Calculators in Varied Populations 58 H. Pragmatic, Evidence-based Dietary Studies 58 I. Comparative Studies of Cardiac Rehabilitation Programs 58 Appendix A: Evidence Review Methodology 59 A. 